<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>3</IssueIDStart>
          <IssueIDEnd>3</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>9</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art2">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>73513</ArticleID>
            <ArticleDOI>10.1208/aapsj070352</ArticleDOI>
            <ArticleSequenceNumber>2</ArticleSequenceNumber>
            <ArticleTitle Language="En">Model-based development of gemcabene, a new lipid-altering agent</ArticleTitle>
            <ArticleFirstPage>E513</ArticleFirstPage>
            <ArticleLastPage>E522</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>3</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>4</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>3</IssueIDStart>
              <IssueIDEnd>3</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff2" PresentAffiliationID="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Jaap</GivenName>
                  <GivenName>W.</GivenName>
                  <FamilyName>Mandema</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(650) 743-9790</Phone>
                  <Email>jmandema@wequantify.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>David</GivenName>
                  <FamilyName>Hermann</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" PresentAffiliationID="Aff4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Wenping</GivenName>
                  <FamilyName>Wang</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Tim</GivenName>
                  <FamilyName>Sheiner</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Mark</GivenName>
                  <FamilyName>Milad</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Rebecca</GivenName>
                  <FamilyName>Bakker-Arkema</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Daniel</GivenName>
                  <FamilyName>Hartman</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>Pharsight Corporation</OrgName>
                <OrgAddress>
                  <Postcode>94040</Postcode>
                  <City>Mountain View</City>
                  <State>CA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgName>Pfizer Global Research and Development</OrgName>
                <OrgAddress>
                  <Postcode>48105</Postcode>
                  <City>Ann Arbor</City>
                  <State>MI</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgName>Quantitative Solutions Inc</OrgName>
                <OrgAddress>
                  <Street>50 Woodside Plaza, Ste 441</Street>
                  <City>Redwood City</City>
                  <State>CA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgName>Johnson &amp; Johnson Pharmaceutical Research and Development LLC</OrgName>
                <OrgAddress>
                  <Postcode>08560</Postcode>
                  <City>Titusville</City>
                  <State>NJ</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The purpose of this study was to evaluate the value of model-based, quantitative decision making during the development of gemcabene, a novel lipid-altering agent. The decisions were driven by a model of the likely clinical profile of gemcabene in comparison with its competitors, such as 3-hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), the cholesterol absorption inhibitor ezetimibe, and their combination. Dose-response models were developed for the lipid effects (low-density lipoprotein cholesterol [LDL-C] and high-density lipoprotein cholesterol); adverse effects, such as persistent alanine aminotransferase elevation and myalgia; tolerability issues, such as headache; and risk reduction for coronary artery disease-related events for 5 statins, ezetimibe, gemcabene, and their combinations. The integrated model was based on the joint analysis of publicly available summary-level data and proprietary patient-level data and included information from almost 10,000 patients. The model was made available and accessible to the development team by using the Pharsight Drug Model Explorer model visualization technology. The modeling greatly enhanced the understanding of the clinical profile of gemcabene when given alone or in combination with a statin. The interaction between statins and gemcabene for the LDL-C lowering effect was found to be significantly different from the interaction between statins and ezetimibe. Ezetimibe was found to have a pharmacological-independent interaction resulting in additional LDL-C lowering over the entire statin dose range. The gemcabene interaction was found to be less than independent, resulting in almost no additional LDL-C lowering at high-statin doses, although the drug has a significant LDL-C effect when administered alone or in combination with a low dose of a statin. The quick availability of the model after completion of the first phase II trial in the target patient population and the ability of the team to explore the potential clinical efficacy and safety of gemcabene in comparison with alternative treatment options facilitated a quick decision to stop development.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>statins</Keyword>
              <Keyword>gemcabene</Keyword>
              <Keyword>ezetimibe</Keyword>
              <Keyword>doseresponse</Keyword>
              <Keyword>LDL</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 7, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_73513.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HB</Initials>
                    <FamilyName>Bays</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>McKenney</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Dujovne</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>92</VolumeID>
                  <FirstPage>538</FirstPage>
                  <LastPage>543</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12943873</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(03)00721-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXms12isLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bays HB, McKenney JM, Dujovne CA, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;92:538–543.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Grundy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JI</Initials>
                    <FamilyName>Cleeman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CN</Initials>
                    <FamilyName>Merz</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ill guidelines</ArticleTitle>
                  <JournalTitle>Circulation</JournalTitle>
                  <VolumeID>110</VolumeID>
                  <FirstPage>227</FirstPage>
                  <LastPage>239</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15249516</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1161/01.CIR.0000133317.49796.0E</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ill guidelines.<Emphasis Type="Italic">Circulation</Emphasis>. 2004;110:227–239.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S-L</Initials>
                    <FamilyName>Normand</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Meta-analysis: formulating, evaluating, combining, and reporting</ArticleTitle>
                  <JournalTitle>Stat Med</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>321</FirstPage>
                  <LastPage>359</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10070677</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/(SICI)1097-0258(19990215)18:3&lt;321::AID-SIM28&gt;3.0.CO;2-P</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1M7mvFyrsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Normand S-L. Meta-analysis: formulating, evaluating, combining, and reporting.<Emphasis Type="Italic">Stat Med</Emphasis>. 1999;18:321–359.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Berry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Berry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>McKellar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TA</Initials>
                    <FamilyName>Pearson</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis</ArticleTitle>
                  <JournalTitle>Am Heart J</JournalTitle>
                  <VolumeID>145</VolumeID>
                  <FirstPage>1036</FirstPage>
                  <LastPage>1045</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12796760</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-8703(03)00106-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXksVyksLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.<Emphasis Type="Italic">Am Heart J</Emphasis>. 2003;145:1036–1045.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JW</Initials>
                    <FamilyName>Mandema</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Cox</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Alderman</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Therapeutic benefit of Eletriptan compared to Sumatriptan for the acute relief of migraine pain—results of a model-based meta-analysis that accounts for encapsulation</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>715</FirstPage>
                  <LastPage>725</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16109054</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1468-2982.2004.00939.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD2Mvkt1agtQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mandema JW, Cox E, Alderman J. Therapeutic benefit of Eletriptan compared to Sumatriptan for the acute relief of migraine pain—results of a model-based meta-analysis that accounts for encapsulation.<Emphasis Type="Italic">Cephalalgia</Emphasis>. 2005;25:715–725.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JW</Initials>
                    <FamilyName>Nawrocki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SR</Initials>
                    <FamilyName>Weiss</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Davidson</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Reductions of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor</ArticleTitle>
                  <JournalTitle>Arterioscler Thromb Vasc Biol</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>678</FirstPage>
                  <LastPage>682</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7749881</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:ByqB28bgtVM%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nawrocki JW, Weiss SR, Davidson MH, et al. Reductions of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.<Emphasis Type="Italic">Arterioscler Thromb Vasc Biol</Emphasis>. 1995;15:678–682.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibUnstructured>U.S. Food and Drug Administration, 2002. NDA 21-445. Zetia (ezetimibe) Medical Reviews. CDER, FDA.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Davidson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>McKenney</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Stein</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>79</VolumeID>
                  <FirstPage>1475</FirstPage>
                  <LastPage>1481</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9185636</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(97)00174-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXktF2jsLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1997;79:1475–1481.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Kafonek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Laurora</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Hunninghake</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study)</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>81</VolumeID>
                  <FirstPage>582</FirstPage>
                  <LastPage>587</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9514454</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(97)00965-X</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXit1Ghtb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study).<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1998;81:582–587.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>U.S. Food and Drug Administration, 1996. NDA 20-702. Lipitor (atorvastatin) Medical Reviews. CDER, FDA.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AG</Initials>
                    <FamilyName>Olsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Pears</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>McKellar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Mizan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Raza</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Effect of Rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>88</VolumeID>
                  <FirstPage>504</FirstPage>
                  <LastPage>508</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11524058</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(01)01727-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmt1Klurk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of Rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2001;88:504–508.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Paoletti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Fahmy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Mahla</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Mizan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Southworth</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with Pravastatin and Sim vastatin in hypercholesterolaemic patients: a randomized, double-blind study</ArticleTitle>
                  <JournalTitle>J Cardiovasc Risk</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>383</FirstPage>
                  <LastPage>390</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11873095</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00043798-200112000-00008</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD387js1Sitg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with Pravastatin and Sim vastatin in hypercholesterolaemic patients: a randomized, double-blind study.<Emphasis Type="Italic">J Cardiovasc Risk</Emphasis>. 2001;8:383–390.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HE</Initials>
                    <FamilyName>Bays</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PB</Initials>
                    <FamilyName>Moore</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Drehobl</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Effectiveness and tolerability of Ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies</ArticleTitle>
                  <JournalTitle>Clin Ther</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>1209</FirstPage>
                  <LastPage>1230</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11558859</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0149-2918(01)80102-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnt1SntLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of Ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.<Emphasis Type="Italic">Clin Ther</Emphasis>. 2001;23:1209–1230.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Davidson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Ma</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EA</Initials>
                    <FamilyName>Stein</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with Rosuvastatin versus Atorvastatin in patients with type IIa or IIb hypercholesterolemia</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>268</FirstPage>
                  <LastPage>275</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11809427</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(01)02226-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xms1GlsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with Rosuvastatin versus Atorvastatin in patients with type IIa or IIb hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2002;89:268–275.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JW</Initials>
                    <FamilyName>Blasetto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EA</Initials>
                    <FamilyName>Stein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WV</Initials>
                    <FamilyName>Brown</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Chitra</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Raza</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Efficacy of Rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>91</VolumeID>
                  <FirstPage>3</FirstPage>
                  <LastPage>10</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(03)00003-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of Rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;91:3–10.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AG</Initials>
                    <FamilyName>Olsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Istad</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Luurila</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Effects of Rosuvastatin and Atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia</ArticleTitle>
                  <JournalTitle>Am Heart J.</JournalTitle>
                  <VolumeID>144</VolumeID>
                  <FirstPage>1044</FirstPage>
                  <LastPage>1051</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12486429</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1067/mhj.2002.128049</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXnvFWh</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Olsson AG, Istad H, Luurila O, et al. Effects of Rosuvastatin and Atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.<Emphasis Type="Italic">Am Heart J.</Emphasis>. 2002;144:1044–1051.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WV</Initials>
                    <FamilyName>Brown</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HE</Initials>
                    <FamilyName>Bays</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DR</Initials>
                    <FamilyName>Hassman</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Efficacy and safety of Rosuvastatin compared with Pravastatin and Simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial</ArticleTitle>
                  <JournalTitle>Am Heart J.</JournalTitle>
                  <VolumeID>144</VolumeID>
                  <FirstPage>1036</FirstPage>
                  <LastPage>1043</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12486428</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1067/mhj.2002.129312</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXnvFWi</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of Rosuvastatin compared with Pravastatin and Simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.<Emphasis Type="Italic">Am Heart J.</Emphasis>. 2002;144:1036–1043.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Dujovne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Ettinger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JF</Initials>
                    <FamilyName>McNeer</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>90</VolumeID>
                  <FirstPage>1092</FirstPage>
                  <LastPage>1097</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12423709</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(02)02798-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xotl2mt7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2002;90:1092–1097.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Davidson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>McGarry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bettis</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Ezetimibe coadministered with Simvastatin in patients with primary hypercholesterolemia</ArticleTitle>
                  <JournalTitle>J Am Coll Cardiol</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>2125</FirstPage>
                  <LastPage>2134</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12505224</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0735-1097(02)02610-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXltFyrtg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with Simvastatin in patients with primary hypercholesterolemia.<Emphasis Type="Italic">J Am Coll Cardiol</Emphasis>. 2002;40:2125–2134.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DW</Initials>
                    <FamilyName>Schneck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RH</Initials>
                    <FamilyName>Knopp</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Ballantyne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>McPherson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RR</Initials>
                    <FamilyName>Chitra</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SG</Initials>
                    <FamilyName>Simonson</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Comparative effects of Rosuvastatin and Atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>91</VolumeID>
                  <FirstPage>33</FirstPage>
                  <LastPage>41</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12505568</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(02)02994-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XpslSmu7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of Rosuvastatin and Atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;91:33–41.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RH</Initials>
                    <FamilyName>Knopp</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Gitter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Truitt</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Effects of Ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia</ArticleTitle>
                  <JournalTitle>Eur Heart J.</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>729</FirstPage>
                  <LastPage>741</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12713767</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0195-668X(02)00807-2</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjtFWmsrY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Knopp RH, Gitter H, Truitt T, et al. Effects of Ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.<Emphasis Type="Italic">Eur Heart J.</Emphasis>. 2003;24:729–741.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Ballantyne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Houri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Notarbartolo</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Effect of Ezetimibe coadministered with Atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial</ArticleTitle>
                  <JournalTitle>Circulation</JournalTitle>
                  <VolumeID>107</VolumeID>
                  <FirstPage>2409</FirstPage>
                  <LastPage>2415</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12719279</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1161/01.CIR.0000068312.21969.C8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjs1antLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of Ezetimibe coadministered with Atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.<Emphasis Type="Italic">Circulation</Emphasis>. 2003;107:2409–2415.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Melani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Mills</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Hassman</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Efficacy and safety of Ezetimibe coadministered with Pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial</ArticleTitle>
                  <JournalTitle>Eur Heart J</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>717</FirstPage>
                  <LastPage>728</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12713766</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0195-668X(02)00803-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjtFWmsrk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Melani L, Mills R, Hassman D, et al. Efficacy and safety of Ezetimibe coadministered with Pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.<Emphasis Type="Italic">Eur Heart J</Emphasis>. 2003;24:717–728.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Kerzner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Corbelli</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Sharp</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia</ArticleTitle>
                  <JournalTitle>Am J Cardiol</JournalTitle>
                  <VolumeID>91</VolumeID>
                  <FirstPage>418</FirstPage>
                  <LastPage>424</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12586255</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9149(02)03236-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXhtVGntLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 2003;91:418–424.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DR</Initials>
                    <FamilyName>Illingworth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DW</Initials>
                    <FamilyName>Erkelens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U</Initials>
                    <FamilyName>Keller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GR</Initials>
                    <FamilyName>Thompson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Tikkanen</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin</ArticleTitle>
                  <JournalTitle>Lancet</JournalTitle>
                  <VolumeID>343</VolumeID>
                  <FirstPage>1554</FirstPage>
                  <LastPage>1556</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7911877</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0140-6736(94)92945-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:ByuB2snmvVI%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.<Emphasis Type="Italic">Lancet</Emphasis>. 1994;343:1554–1556.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MR</Initials>
                    <FamilyName>Law</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NJ</Initials>
                    <FamilyName>Wald</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AR</Initials>
                    <FamilyName>Rudnicka</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis</ArticleTitle>
                  <JournalTitle>BMJ</JournalTitle>
                  <VolumeID>326</VolumeID>
                  <FirstPage>1423</FirstPage>
                  <LastPage>1430</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12829554</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1136/bmj.326.7404.1423</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXlvFCjsLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.<Emphasis Type="Italic">BMJ</Emphasis>. 2003;326:1423–1430.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
